These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 12473799)

  • 21. Screening for Chlamydia trachomatis: a systematic review of the economic evaluations and modelling.
    Roberts TE; Robinson S; Barton P; Bryan S; Low N;
    Sex Transm Infect; 2006 Jun; 82(3):193-200; discussion 201. PubMed ID: 16731666
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The program cost and cost-effectiveness of screening men for Chlamydia to prevent pelvic inflammatory disease in women.
    Gift TL; Gaydos CA; Kent CK; Marrazzo JM; Rietmeijer CA; Schillinger JA; Dunne EF
    Sex Transm Dis; 2008 Nov; 35(11 Suppl):S66-75. PubMed ID: 18830137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Opportunistic screening for genital infections with Chlamydia trachomatis in sexually active population of Amsterdam. II. Cost-effectiveness analysis of screening women].
    Ruitenberg EN
    Ned Tijdschr Geneeskd; 1999 May; 143(19):1012. PubMed ID: 10368724
    [No Abstract]   [Full Text] [Related]  

  • 24. Screening for Chlamydia trachomatis in asymptomatic women in Hungary. An epidemiological and cost-effectiveness analysis.
    Nyári T; Nyári C; Woodward M; Mészáros G; Deák J; Nagy E; Kovács L
    Acta Obstet Gynecol Scand; 2001 Apr; 80(4):300-6. PubMed ID: 11264602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness analysis of Chlamydia trachomatis screening via internet-based self-collected swabs compared with clinic-based sample collection.
    Huang W; Gaydos CA; Barnes MR; Jett-Goheen M; Blake DR
    Sex Transm Dis; 2011 Sep; 38(9):815-20. PubMed ID: 21844736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Should all sexually active young women in Hungary be screened for Chlamydia trachomatis?
    Nyári T; Woodward M; Kovács L
    Eur J Obstet Gynecol Reprod Biol; 2003 Jan; 106(1):55-9. PubMed ID: 12475582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Screening and treating Chlamydia trachomatis genital infection to prevent pelvic inflammatory disease: interpretation of findings from randomized controlled trials.
    Gottlieb SL; Xu F; Brunham RC
    Sex Transm Dis; 2013 Feb; 40(2):97-102. PubMed ID: 23324973
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estimation of the burden of disease and costs of genital Chlamydia trachomatis infection in Canada.
    Tuite AR; Jayaraman GC; Allen VG; Fisman DN
    Sex Transm Dis; 2012 Apr; 39(4):260-7. PubMed ID: 22421691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systematic screening for Chlamydia trachomatis: estimating cost-effectiveness using dynamic modeling and Dutch data.
    de Vries R; van Bergen JE; de Jong-van den Berg LT; Postma MJ;
    Value Health; 2006; 9(1):1-11. PubMed ID: 16441519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. What is the cost of pelvic inflammatory disease and how much could be prevented by screening for chlamydia trachomatis? Cost analysis of the Prevention of Pelvic Infection (POPI) trial.
    Aghaizu A; Adams EJ; Turner K; Kerry S; Hay P; Simms I; Oakeshott P
    Sex Transm Infect; 2011 Jun; 87(4):312-7. PubMed ID: 21444333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of widespread screening for Chlamydia trachomatis.
    Postma MJ; Welte R; Morré SA
    Expert Opin Pharmacother; 2002 Oct; 3(10):1443-50. PubMed ID: 12387690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of natural history parameters on the cost-effectiveness of Chlamydia trachomatis screening strategies.
    Hu D; Hook EW; Goldie SJ
    Sex Transm Dis; 2006 Jul; 33(7):428-36. PubMed ID: 16572038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness analysis of screening adolescent males for Chlamydia on admission to detention.
    Blake DR; Gaydos CA; Quinn TC
    Sex Transm Dis; 2004 Feb; 31(2):85-95. PubMed ID: 14743071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Point-of-entry screening for C. trachomatis In female army recruits. Who derives the cost savings?
    Howell MR; McKee KTJr ; Gaydos JC; Quinn TC; Gaydos CA
    Am J Prev Med; 2000 Oct; 19(3):160-6. PubMed ID: 11020592
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Swedish cost-effectiveness analysis of community-based Chlamydia trachomatis PCR testing of postal urine specimens obtained at home.
    Novak DP; Lindholm L; Jonsson M; Karlsson RB
    Scand J Public Health; 2004; 32(5):324-32. PubMed ID: 15513664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-Effectiveness of Opt-Out Chlamydia Testing for High-Risk Young Women in the U.S.
    Owusu-Edusei K; Hoover KW; Gift TL
    Am J Prev Med; 2016 Aug; 51(2):216-224. PubMed ID: 26952078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Potentials of screening for Chlamydia trachomatis in Hungary: cost-benefit analysis].
    Nyári T; Mészáros G; Deák J; Nagy E; Kovács L
    Orv Hetil; 2000 Jul; 141(27):1511-6. PubMed ID: 10943109
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness and cost-effectiveness of a pharmacy-based screening programme for Chlamydia trachomatis in a high-risk health centre population in Amsterdam using mailed home-collected urine samples.
    van Bergen JE; Postma MJ; Peerbooms PG; Spangenberg AC; Tjen-A-Tak J; Bindels PJ
    Int J STD AIDS; 2004 Dec; 15(12):797-802. PubMed ID: 15601485
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cost and cost-effectiveness of opportunistic screening for Chlamydia trachomatis in Ireland.
    Gillespie P; O'Neill C; Adams E; Turner K; O'Donovan D; Brugha R; Vaughan D; O'Connell E; Cormican M; Balfe M; Coleman C; Fitzgerald M; Fleming C
    Sex Transm Infect; 2012 Apr; 88(3):222-8. PubMed ID: 22213681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk assessment and other screening options for gonorrhoea and chlamydial infections in women attending rural Tanzanian antenatal clinics.
    Mayaud P; Grosskurth H; Changalucha J; Todd J; West B; Gabone R; Senkoro K; Rusizoka M; Laga M; Hayes R
    Bull World Health Organ; 1995; 73(5):621-30. PubMed ID: 8846488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.